[Allergy to antitubercular agents; with special reference to new drugs].
D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000707:Anaphylaxis / Q000139:chemically induced; D000995:Antitubercular Agents / Q000009:adverse effects*; D002207:Capreomycin / Q000009:adverse effects; D003523:Cycloserine / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000209:etiology*; D004977:Ethambutol / Q000009:adverse effects; D005000:Ethionamide / Q000009:adverse effects; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D007612:Kanamycin / Q000009:adverse effects; D011718:Pyrazinamide / Q000009:adverse effects; D012293:Rifampin / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced; D014756:Viomycin / Q000009:adverse effects
D000995:Antitubercular Agents; D002207:Capreomycin; D011718:Pyrazinamide; D007612:Kanamycin; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D014756:Viomycin
Allergie gegen Tuberkulostatika; Unter besonderer Berücksichtigung neuer Mittel.